From the European Society for Medical Oncology 2012 Congress: Additional safety, tolerability data for tivozanib versus sorafenib in metastatic RCC shows fewer adverse events

November 1, 2012

New data demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first-line setting for patients with metastatic renal cell carcinoma (RCC), was presented at ESMO's 2012 Congress.

Related Content:

News | Clinical Pharmacology